Treatment of COVID-19 patients (Photo: VNA)
|
The COVID-19 treatment drug is based on polyclonal antibodies that targets COVID-19 patients with moderate conditions.
The first and second phases of XAV-19 clinical trials’ results showed that the drug is effective and safe in preventing the virus to develop, neutralizing the virus and reducing inflammation in patients. The third phase of XAV-19 clinical trials is being conducted in some European countries.
Odile Duvaux, president of the French pharmaceutical company said his company is willing to cooperate with Vietnam in implementing the third phase of the trials, and to engage in further discussions on the transfer of the drug production technology to Vietnam.